Piper Jaffray: Forest Laboratories Speaks With Physician Expert About Daliresp

Piper Jaffray released a research report on Forest Laboratories (NASDAQ: FRX) announcing there is mixed feedback on Daliresp from a physician expert.

In the report, Piper Jaffray writes, “We hosted a call with Dr. James Donohue, a thought leader in chronic obstructive pulmonary disease (COPD) and investigator in studies of Daliresp. Though Dr. Donohue noted that patients with severe COPD have limited treatment options, Daliresp's modest benefit in terms of lowering exacerbation risk, limited benefit in terms of symptom relief, and issues regarding gastrointestinal (GI) side effects make it hard for us to envision the product being more than a niche player in the COPD space”

Piper Jaffray has an Underweight rating and a $29.00 price target on Forest Laboratories, which closed yesterday at $34.10.